drughunter.com
5 minute read
Dec. 28, 2022

Mobocertinib: The First Approved EGFRex20 Mutant Inhibitor

mobocertinib

EGFR exon 20 mutant inhibitor, oral once-daily FDA-approved for EGFR ex20+ NSCLC from cellular screening + SBDD Bioorg. Med. Chem. Lett., 21 November 2022 ARIAD/Takeda, Cambridge, MA

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in